Home›Pregabalin Capsules, Cv

Pregabalin Capsules, Cv

Also known as: Pregabalin Capsules, Cv

Route: Oral

Check Pregabalin Capsules, Cv Interactions →

3 interactions on record

Pregabalin Capsules, Cv has 3 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Alcohol, Lorazepam, Oxycodone. Patients taking Pregabalin Capsules, Cv should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 3
Moderate: 3

Moderate (3)

Pregabalin Capsules, Cv + Alcohol— Additive effects on cognitive and gross motor functioning when co-administered with pregabalin.
Pregabalin Capsules, Cv + Lorazepam— Additive effects on cognitive and gross motor functioning when co-administered with pregabalin.
Pregabalin Capsules, Cv + Oxycodone— Additive effects on cognitive and gross motor functioning when co-administered with pregabalin.

Pregabalin Capsules, Cv + Alcohol🟡Moderate

Additive effects on cognitive and gross motor functioning when co-administered with pregabalin.

Pregabalin Capsules, Cv + Lorazepam🟡Moderate

Additive effects on cognitive and gross motor functioning when co-administered with pregabalin.

Pregabalin Capsules, Cv + Oxycodone🟡Moderate

Additive effects on cognitive and gross motor functioning when co-administered with pregabalin.

Contraindications

4 CONTRAINDICATIONS Pregabalin is contraindicated in patients with known hypersensitivity to pregabalin or any of its components. Angioedema and hypersensitivity reactions have occurred in patients receiving pregabalin therapy [see Warnings and Precautions ( 5.2 )] . Known hypersensitivity to pregabalin or any of its components. ( 4 )

Pregnancy & Breastfeeding

8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to pregabalin during pregnancy. To provide information regarding the effects of in utero exposure to pregabalin, physicians are advised to recommend that pregnant patients taking pregabalin enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org/ . Risk Summary Observational studies on the use of pregabalin during pregnancy suggest a possible small increase in the rate of overall major birth defects, but there was no consistent or specific pattern of major birth defects identified (see Data). Available postmarketing data on miscarriage and other maternal, fetal, and long term developmental adverse effects were insufficient to identify risk associated with pregabalin. Postmarketing data suggest that extended gabapentinoid use with opioids close to delivery may increase the risk of neonatal withdrawal versus opioids alone (see Clinical Considerations). There are no comparative epidemiologic studies evaluating this association. Therefore, it is not known whether exposure to pregabalin alone late in pregnancy may cause withdrawal signs and symptoms. In animal reproduction studies, increased incidences of fetal structural abnormalities and other manifestations of developmental toxicity, including skeletal malformations, retarded ossification, and decreased fetal body weight were observed in the offspring of rats and rabbits given pregabalin orally during organogenesis, at doses that produced plasma pregabalin exposures (AUC) greater than or equal to 16 times human exposure at the maximum recommended dose (MRD) of 600 mg/day (see Data) . In an animal development study, lethality, growth retardation, and nervous and reproduct

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.